TG Therapeutics, Inc.
TGTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $4,374,042 | $2,424,593 | $1,601,915 | $2,512,232 |
| - Cash | $179,894 | $92,933 | $102,304 | $298,887 |
| + Debt | $254,380 | $110,795 | $83,060 | $79,047 |
| Enterprise Value | $4,448,528 | $2,442,455 | $1,582,671 | $2,292,392 |
| Revenue | $329,004 | $233,662 | $2,785 | $6,689 |
| % Growth | 40.8% | 8,290% | -58.4% | – |
| Gross Profit | $290,518 | $219,531 | $2,520 | $5,899 |
| % Margin | 88.3% | 94% | 90.5% | 88.2% |
| EBITDA | $49,902 | $26,100 | -$213,106 | -$341,969 |
| % Margin | 15.2% | 11.2% | -7,651.9% | -5,112.4% |
| Net Income | $23,383 | $12,672 | -$223,812 | -$348,101 |
| % Margin | 7.1% | 5.4% | -8,036.3% | -5,204.1% |
| EPS Diluted | 0.15 | 0.085 | -1.46 | -2.63 |
| % Growth | 75.8% | 105.8% | 44.5% | – |
| Operating Cash Flow | -$40,517 | -$31,413 | -$176,170 | -$295,634 |
| Capital Expenditures | -$45 | $0 | -$14 | -$401 |
| Free Cash Flow | -$40,562 | -$31,413 | -$176,184 | -$296,035 |